Rhinovirus Exacerbates House-Dust-Mite Induced Lung Disease in Adult Mice

Jennifer A. Phan1,2, Anthony Kicic1,3,4,5, Luke J. Berry1,3, Lynette B. Fernandes2, Graeme R. Zosky1,3, Peter D. Sly6, Alexander N. Larcombe1,3,*

1 Division of Clinical Sciences, Telethon Institute for Child Health Research, The University of Western Australia, Subiaco, Western Australia, Australia, 2 Pharmacology, Pharmacy and Anaesthesiology Unit, School of Medicine and Pharmacology, The University of Western Australia, Crawley, Western Australia, Australia, 3 School of Paediatrics and Child Health, The University of Western Australia, Subiaco, Western Australia, Australia, 4 Department of Respiratory Medicine, Princess Margaret Hospital for Children, Perth, Western Australia, Australia, 5 Centre for Cell Therapy and Regenerative Medicine, School of Medicine and Pharmacology, The University of Western Australia, Crawley, Western Australia, Australia, 6 Queensland Children’s Medical Research Institute, The University of Queensland, Brisbane, Queensland, Australia

Abstract

Human rhinovirus is a key viral trigger for asthma exacerbations. To date, murine studies investigating rhinovirus-induced exacerbation of allergic airways disease have employed systemic sensitisation/intranasal challenge with ovalbumin. In this study, we combined human-rhinovirus infection with a clinically relevant mouse model of aero-allergen exposure using house-dust-mite in an attempt to more accurately understand the links between human-rhinovirus infection and exacerbations of asthma. Adult BALB/c mice were intranasally exposed to low-dose house-dust-mite (or vehicle) daily for 10 days. On day 9, mice were inoculated with human-rhinovirus-1B (or UV-inactivated human-rhinovirus-1B). Forty-eight hours after inoculation, we assessed bronchoalveolar cellular inflammation, levels of relevant cytokines/serum antibodies, lung function and responsiveness/sensitivity to methacholine. House-dust-mite exposure did not result in a classical TH2-driven response, but was more representative of noneosinophilic asthma. However, there were significant effects of house-dust-mite exposure on most of the parameters measured including increased cellular inflammation (primarily macrophages and neutrophils), increased total IgE and house-dust-mite-specific IgG1 and increased responsiveness/sensitivity to methacholine. There were limited effects of human-rhinovirus-1B infection alone, and the combination of the two insults resulted in additive increases in neutrophil levels and lung parenchymal responses to methacholine (tissue elastance). We conclude that acute rhinovirus infection exacerbates house-dust-mite-induced lung disease in adult mice. The similarity of our results using the naturally occurring allergen house-dust-mite, to previous studies using ovalbumin, suggests that the exacerbation of allergic airways disease by rhinovirus infection could act via multiple or conserved mechanisms.

Introduction

It has been known for over forty years that respiratory tract viral infections are a key trigger of exacerbations of respiratory conditions such as bronchitis [1,2] and asthma [3]. With the advent of more specific diagnostic technologies such as RT-PCR, it became evident that a significant proportion of asthma exacerbations and hospital admissions for asthma were associated with a human rhinovirus (HRV) infection [4]. Further, these technologies confirmed that HRV is not just an infection of the upper respiratory tract, but rather that it is able to infect and replicate in the lower airways [3]. The association between HRV infection and asthma exacerbation has been observed in both children [6,7,8] and adults [9,10].

Many mechanisms of HRV-induced exacerbation of asthma have been suggested, including altered pulmonary inflammation/cytokine profiles [11], increased susceptibility of asthmatic patients to HRV infection [12] and HRV-induced damage to the airway epithelium [13]. Indeed, controlled infection studies in humans have shown increased airway inflammation, and more severe coryzal symptoms, such as wheeze, in HRV-infected asthmatics [5,14]. However, further investigation into these potential mechanisms has been slow due to the lack of suitable in vivo models which combine HRV infection and allergic airways disease. Previous in vivo studies have infected mice with a minor group virus, most notably HRV-1B, and systemically sensitised/intranasally challenged them with ovalbumin [15,16,17]. HRV-1B is closely related to HRV-16 [18], the serotype most often used in human infection studies [19]. BALB/c mice infected with HRV-1B develop rapid neutrophilic inflammation as well as peribronchial/perivascular cellular infiltration of macrophages and lymphocytes [15,16]. Mice previously sensitised and then challenged with ovalbumin and infected with HRV-1B show increases in cellular inflammation, lung expression of cytokines including eotaxin-1, IL-4, IL-13 and IFN-γ, mucus secretion and respiratory system resistance (Rrs) compared with controls [15,16]. In many of these studies, neutrophilic inflammation of the lower airways was demonstrated to be a feature of asthma exacerbations [15,16,17,20,21,22,23,24]. Variations on the murine ovalbumin...
model of allergic airways disease have been used for many years, despite some recent concerns about their applicability to the human condition [25,26]. In particular, mice systemically sensitized to ovalbumin in conjunction with aluminium hydroxide and then challenged with inhaled ovalbumin do not exhibit epithelial damage and remodelling as seen in asthma sufferers. To address this, we exposed mice to house dust mite (HDM; *Dermatophagoides pteronyssinus*) prior to HRV-1B infection. HDM exposure has some advantages over traditional ovalbumin models in that it is a naturally occurring allergen which causes atopic sensitization (via the nasal mucosa), allergic airways disease, and damage to the airway epithelium in humans [27,28,29]. High protein content HDM also induces an asthmatic phenotype in mice, including elevated IgE and TH2 cytokines, eosinophilia, increased airway smooth muscle, collagen deposition and increased Rrs [27,30] without the need for chemical adjuvants.

In this study, we aimed to investigate the effects of HRV-1B infection on HDM-induced airways disease. This was achieved by exposing adult female BALB/c mice to low doses of HDM via the nasal mucosa prior to infection with HRV-1B. Forty-eight hours after infection, we assessed bronchoalveolar lavage inflammation as previously described [27].

**Virus and infection**

A laboratory strain of rhinovirus, HRV-1B was kindly provided by Prof. Peter Wark (Hunter Medical Research Institute, Newcastle, NSW, Australia). We used HRV-1B (a minor group HRV) as it binds to members of the low density lipoprotein (LDL) receptor family in mice [13,32]. Since mice lack the intercellular adhesion molecule 1 (ICAM-1) receptor utilised by the majority of HRV serotypes only minor-group HRV serotypes are able to cause infection in this species [33].

HRV-1B was propagated on HeLa cells as described previously [34,35]. After 24 hours of incubation at 35°C, 5×10⁶ infected cells were detached using a cell scraper and resuspended in PBS to a total volume of 15 mL. Cells were then lysed with the addition of 10% (v/v) n-octyl phenoxypolyethoxylethanol (NP-40), and cell debris pelleted by centrifugation at 10,000 rpm at 4°C for 10 minutes. Supernatant fluid was supplemented with the addition of 200 μg RNase A and incubated at 35°C for 20 minutes to disrupt ribosomes. HRV-1B was then pelleted utilizing 0.1% Bovine Serum Albumin (BSA), layered on two linear 5 mL gradients (7.5 to 45% sucrose in PBSa) and centrifuged for 2 hours at 16°C at 40,000 rpm. The purified viral band was then removed from the gradient using a Pasteur pipette and stored at −80°C. Virus concentration was measured using Nanodrop spectrophotometer OD260 measurement as previously described [36]. Virus infectivity was determined using MRC5 cells and calculated using the Spearman–Karber estimation of TCID₅₀ [37].

Under light methoxyflurane anaesthesia mice were intranasally inoculated with 1×10⁹ TCID₅₀ HRV-1B in 50 μL Dulbecco’s Modified Eagle Medium (DMEM; Sigma-Aldrich Pty Ltd, Sydney, Australia) or inactivated virus (control) in DMEM. This was done 48 hours prior to study. Virus was inactivated by exposing it to UV-light for 3 hours and heating it to 57°C for 2 hours.

**Materials and Methods**

**Ethics statement**

This study was carried out in strict accordance with the recommendations of the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes (7th Edition). The protocol was approved by The Telethon Institute for Child Health Research Animal Ethics Committee (approvals #216 and #220). All surgeries were performed under general anaesthesia and all efforts were made to minimize suffering.

**Animals**

Adult female (7-weeks) BALB/c mice were obtained from Animal Resources Centre (Murdock, WA, Australia) and housed at the Telethon Institute for Child Health Research (TICHR) in specific pathogen-free environments. Mice were maintained on a 12:12 hour light:dark cycle and supplied with an allergen free diet (Specialty Feeds, Glen Forrest, WA, Australia) and acidified water ad libitum.

**House dust mite sensitisation**

Mice were lightly anaesthetised with methoxyflurane (Medical Development International Ltd, Springvale, Victoria, Australia) and intranasally inoculated with 25 μg of *Dermatophagoides pteronyssinus* protein (HDM: 17.35% w/w protein, 12.47 EU/mg; Greer Laboratories, Lenoir, NC, USA) dissolved in 50 μL of saline or saline alone (vehicle) by pipetting drops onto the nostrils until aspirated. This is the equivalent of approximately 144 μg of whole-crushed HDM. Mice received inoculations for ten consecutive days as previously described [27].
microscopy using an Olympus BX43 System Microscope (Olympus Australia Pty. Ltd., Mount Waverely, Australia).

Lung function and responsiveness to methacholine

All in vivo studies were conducted 48 hours after HRV-1B inoculation, which coincided with 24 hours after the last HDM exposure (the “day-of-study”). This timing was based on preliminary kinetics studies which showed that the peak of HRV-1B induced pulmonary inflammation occurs 48 hours post infection in adult female BALB/c mice (Figure S1). Mice were surgically prepared, and lung function/responsiveness to methacholine (MCh; acetyl β-methacholine chloride, Sigma-Aldrich, MO, USA) was assessed as previously described [38]. Briefly, we used a modification of the low frequency forced oscillation technique (FOT) to measure respiratory system impedance (Zrs) [31]. We fit the single compartment and constant phase models to Zrs to generate respiratory system resistance (Rrs) and to partition tissue damping and tissue elastance to increase by 150% dose required for respiratory system resistance, airway resistance, the ratio of G/H [39]. Sensitivity to MCh was calculated as the resistance to MCh were compared using two-way ANOVA with Holm-Sidak post-hoc tests. Data were transformed where appropriate and are reported as mean ± SD. p<0.05 was considered significant.

Results

Mass

Prior to experimentation, there were no differences in the mass of mice randomly allocated to the different treatment groups. HRV-1B infection resulted in significant weight loss (p = 0.013) in that infected mice were significantly lighter on the day of study (17.39±0.95 g) compared to the same mice on the day of infection (18.20±1.00 g) regardless of HDM-exposure. On the day of study, there were no differences in average mass between the different treatment groups (p>0.575 in all cases).

Confirmation of HRV infection

Mouse lungs were formalin fixed, embedded in paraffin and stained for HRV-1B. Figure 1 shows typical staining patterns for uninfected (Figure 1A and 1C) and infected (Figure 1B and 1D) mice. Immunohistochemical staining specific for HRV-1B infection was identifiable in mice infected with HRV-1B (Figure 1B and 1D), but not in mice treated with inactivated HRV-1B (Figure 1A and 1C). HRV-1B infection had obvious cytopathological effects including epithelial cell shedding and possible disruption of epithelial barrier integrity. As shown previously, HRV-1B staining was patchy and positive staining (brown colour) was observed in groups of epithelial cells in close proximity [21,41]. There was no apparent visual difference in immunohistochemical stained lung sections obtained from Sal-HRV (Figure 1B) and HDM-HRV (Figure 1D) mice.

Cellular inflammation

There was a significant interaction between HRV-infection and HDM-exposure with respect to total bronchoalveolar lavage fluid (BAL) cellularity. BAL fluid was collected by slowly washing 0.5 mL of saline in and out of the lungs three times via the tracheal cannula. The samples were centrifuged at 2000 rpm for 4 minutes and the supernatant collected for cytokine analysis by ELISA. The pellet was resuspended in phosphate buffered saline (PBS) and a 10 μL sample taken, stained with trypan blue and cells were counted using a haemocytometer. The resuspended BAL fluid was cytospun onto microscope slides and stained with Leishmann’s stain for differential cell counts by light microscopy. Levels of BAL IL-5, IL-13, MIP-2 and IFN-γ were measured using ELISA as per the manufacturer’s instructions (BD Biosciences, San Diego, CA, USA). Total protein content was measured using a colorimetric assay (Bio-Rad, Gladesville, NSW, Australia) [40].

Serum antibodies

Following in vivo measurements, blood was collected via cardiac puncture. Samples were centrifuged at 2000 rpm for 15 minutes and the serum taken for analysis of total IgE and HDM specific IgG1 levels by ELISA. HDM specific IgG1 was measured as previously described [27]. Levels of total IgE were measured as per the manufacturer’s instructions (BD Biosciences, San Diego, CA, USA).

Statistics

All data were analysed using SigmaPlot 12.5 (SPSS Science, Chicago, IL, USA). Lung function, inflammation and responsiveness to MCh were compared using two-way ANOVA with Holm-Sidak post-hoc tests. Data were transformed where appropriate and are reported as mean ± SD. p<0.05 was considered significant.

Figure 1. Variable lung pathology in mice infected with HRV-1B (or control) and exposed to HDM (or control). Adult female BALB/c mice were exposed to 25 μg of HDM protein (or control) daily for 10 days. On day 9 they were infected with 1×10⁵ TCID₅₀ HRV-1B or inactivated virus. Samples were harvested 48 hours after infection. Representative images of immunohistochemical stained formalin fixed sections are shown - (A) Saline-iHRV, (B) Saline-HRV, (C) HDM-iHRV and (D) HDM-HRV. Infected mice show clear positive staining and an altered epithelium. Bars represent 50 μm.

doi:10.1371/journal.pone.0092163.g001
and HDM-exposure on neutrophil numbers with HDM-HRV mice having significantly more BAL neutrophils (36149 ± 622871 cells/mL) compared with mice exposed to either insult alone (Sal-HRV = 9125 ± 6577 cells/mL and HDM-iHRV = 18669 ± 15477 cells/mL; p<0.012 in both cases).

Serum antibodies

Mice exposed to HDM had significantly higher total IgE (p = 0.041; Figure 3A) and HDM specific IgG1 (p = 0.009; Figure 3B) in their serum compared with non-exposed mice (Figure 3). There was no effect of HRV-1B-infection on levels of either antibody (p>0.250 in both cases), nor was there any interaction (p>0.675 in both cases).

Mediators and protein

There was a significant effect of HDM-exposure on levels of MIP-2 (p = 0.021; Figure 4A), IFN-α (p = 0.044; Figure 4B) and IL-13 (p = 0.027; Figure 4C) in BAL (Figure 4). HDM-exposure was associated with lower levels of IFN-α, IL-13, and higher levels of MIP-2 compared with saline-exposed mice. HDM exposure did not significantly alter total protein levels (p = 0.105; Figure 4D). There was no effect of HRV-1B infection on IL-13, MIP-2, IFN-α or protein levels (p = 0.312 in all cases), nor was there any interaction between HRV-1B-infection and HDM-exposure (p = 0.418 in all cases). IL-5 was not detected in the BAL of any treatment group (limit of detection 55.25 pg/mL), consistent with the absence of eosinophils.

Baseline lung mechanics

There were complex interactions between HDM-exposure and HRV-1B-infection with respect to baseline airway resistance (Rnw) and tissue damping (G) (Table 1). Both HRV-1B-infection and HDM-exposure were required to cause a significant increase in baseline Rnw. HDM-HRV mice had a significantly higher baseline airway resistance compared with HDM-iHRV and Sal-HRV mice.
There was no effect of either HDM alone (p = 0.874), or HRV1B-infection alone (p = 0.262) on baseline Raw. A similar effect was seen for tissue elastance (H), whereby HDM-HRV mice had significantly higher baseline H compared with mice exposed to either insult alone (p = 0.002). There was no effect of HDM alone (p = 0.598) or HRV-1B-infection alone (p = 0.528) on baseline G. HDM-exposure significantly increased baseline G (p = 0.009) and baseline respiratory system resistance (Rrs) (p = 0.003), however there was no effect of HRV-1B-infection on either of these parameters (p > 0.343 in both cases). Further, there was no interaction between HRV-1B and HDM with respect to baseline G. There was no effect of HRV-1B-infection or HDM-exposure on baseline hysteresivity (η), nor was there any interaction between HRV-1B-infection and HDM-exposure for this parameter (p > 0.07 in all cases).

Responsiveness to methacholine
Responsiveness to MCh was significantly influenced by HDM-exposure, with HDM-exposed mice having significantly higher Rrs (Figure 5A), Raw (Figure 5B) and G (Figure 5C) at the maximum dose of MCh (p < 0.026 in all cases). There was no effect of HRV-1B-infection, or any interaction between the two insults for maximum Rrs, maximum Raw or maximum G (p > 0.200 in all cases). There was, however, a significant interaction between HDM-exposure and HRV-1B-infection with respect to H at the maximum dose of MCh (Figure 5D) whereby HDM-HRV treated mice had a significantly higher H compared with mice exposed to either insult alone (p < 0.001). There was no effect of either insult alone on maximum H (p > 0.367 in both cases).

**Table 1.** Baseline lung function as measured by the forced oscillation technique of mice exposed to HDM, infected with HRV or both.

|                  | SalHRV (n = 8) | SalHRV (n = 9) | HDMiHRV (n = 10) | HDMHRV (n = 10) |
|------------------|----------------|----------------|------------------|-----------------|
| Raw              | 0.309 ± 0.03   | 0.293 ± 0.04   | 0.307 ± 0.02     | 0.337 ± 0.02b   |
| Rrs              | 0.516 ± 0.06   | 0.510 ± 0.07   | 0.558 ± 0.05a    | 0.599 ± 0.06a   |
| G                | 6.17 ± 0.88    | 5.99 ± 0.96    | 6.49 ± 0.65a     | 7.21 ± 0.95a    |
| H                | 36.20 ± 7.03   | 34.14 ± 7.05   | 38.24 ± 5.27     | 44.95 ± 8.45b   |
| η                | 0.17 ± 0.01    | 0.18 ± 0.01    | 0.17 ± 0.01      | 0.16 ± 0.01     |

a = effect of HDM, b = combined effect of HRV and HDM. Data are mean ± standard deviation.
doi:10.1371/journal.pone.0092163.t001

Figure 4. HDM exposure results in increased MIP-2 and decreased IFNα and IL-13. Adult female BALB/c mice were exposed to 25 μg of HDM protein (or control) daily for 10 days. On day 9 they were infected with 1 × 10⁸ TCID₅₀ HRV-1B or inactivated virus. Samples were harvested 48 hours after infection. HDM exposure increased bronchoalveolar lavage MIP-2 (A), and decreased IFNα (B) and IL13 (C). There was no effect of HDM exposure on BAL protein (D), nor were there any effects of HRV-1B infection alone, or combined effects of HDM exposure and HRV-1B infection on any of these parameters. * indicates a significant difference between groups. n = 8 to 10 per treatment. Data are mean ± standard deviation. doi:10.1371/journal.pone.0092163.g004
Sensitivity to methacholine

Mice exposed to HDM had significantly lower RsEC150 (Figure 6B), GEC150 (Figure 6C) and HEC150 (Figure 6D) values compared to non-exposed mice (p = 0.001 in all cases). There was no effect of HDM-exposure on RawEC150 (p = 0.176; Figure 6A), nor was there an effect of HRV-1B-infection on sensitivity to MCh for any parameter (p > 0.159 in all cases). Although there was a trend towards the greatest sensitivity to MCh for HDM-HRV mice for all parameters, this was not significant.

Discussion

The results of this study illustrate that HRV-1B infection can influence the response of adult mice to short-term HDM exposure. We did not see HRV-1B-induced exacerbation of “traditional” TH2 dominated allergic airways disease parameters such as airway responsiveness to methacholine, or bronchoalvolar lavage eosinophilia, but rather the additive effects of HRV-1B infection and HDM-exposure were in terms of increased neutrophilia and impaired parenchymal mechanics. These findings suggest that the model described in the current study could be more representative of a noneosinophilic asthma phenotype. This is supported by a number of murine studies of allergic asthma which propose a dissociation between airway hyperresponsiveness and “traditional” TH2 measures such as IL-5, IgE and eosinophilia [42,43,44]. Further, a recent study in humans shows that approximately half of patients with mild-to-moderate asthma have persistently noneosinophilic disease [45].

Combining short-term HDM-exposure and HRV-1B infection resulted in additive effects with respect to pulmonary neutrophilia, and some measures of lung function (Figures 2 and 5). While there was also a trend towards increased sensitivity to MCh for Rs, Rs, G and H, these were not significant (Figure 6). The additive effect of the two insults on BAL neutrophilia is commonly seen in similar studies employing ovalbumin [15,16,17]. Further, neutrophils are found in greater numbers in the nasal secretions, sputum, and BAL of allergic humans experimentally infected with un-purified HRV-16, compared with healthy controls [46,47]. In our study, neutrophilia was associated with higher levels of MIP-2 (the mouse analogue of IL-8). These data support the notion that HRV infection may contribute to asthma exacerbation via augmentation of existing inflammation by enhancing the production of neutrophils and related chemoattractants [49]. Thus, while the pathology induced by the ovalbumin and HDM models is different, the apparent impact

Figure 5. Exacerbation of parenchymal responsiveness to MCh by the combination of HDM exposure and HRV-1B infection. Adult female BALB/c mice were exposed to 25 μg of HDM protein (or control) daily for 10 days. On day 9 they were infected with 1 x 10⁶ TCID₅₀ HRV-1B or inactivated virus. Measurements were made 48 hours after infection. We partitioned respiratory system impedance into airway resistance (A), respiratory system resistance (B), tissue damping (C) and tissue elastance (D). HDM exposure induced a greater response to MCh challenge with respect to airway resistance and respiratory system resistance. There was exacerbation of tissue responsiveness due to the combination of the two insults.* indicates a significant effect of HDM-exposure; # indicates an additive effect of HDM and HRV-1B. n = 8 to 10 per treatment. Data are mean ± standard deviation. doi:10.1371/journal.pone.0092163.g005
of HRV on disease exacerbation is similar. This suggests that viral exacerbation of asthma is not necessarily through traditional TH2 pathways.

We did not measure any further increase in airway hyper-responsiveness ($R_{aw}$ as defined by the constant phase model) or respiratory system resistance ($R_{rs}$ as defined by the single compartment model) in HDM-exposed mice also infected with HRV-1B, above that seen in mice exposed to HDM only. Previous studies combining HRV-1B infection with ovalbumin models of allergic airways disease [15,16] have shown additive effects of systemic sensitisation and challenge with ovalbumin and HRV-1B infection on $R_{aw}$. Unfortunately, these studies do not report changes in lung compliance or elastance and none use the constant phase model to partition respiratory system impedance into parameters representing the airways ($R_{aw}$) and lung parenchyma ($G$ and $H$). Instead, these studies use the widely discredited “enhanced pause” technique [50] or the single-compartment model to obtain an estimate of $R_{rs}$. Respiratory system resistance includes a significant contribution from parts of the lung other than the main conducting airways, such that it is difficult to interpret from an asthma exacerbation (ie bronchoconstriction) point of view, if one assumes asthma is primarily an airways disease. Conversely, as $R_{aw}$ is a measure of airway resistance, it would be expected to change if the airways are significantly narrowed [51], suggesting that, in our study, combining HRV-infection and HDM-exposure did not narrow the airways more than HDM-exposure alone. Instead, the combination of HRV-infection and HDM-exposure significantly increased tissue elastance ($H$). Changes in $H$ have been interpreted as lung de-recruitment [32] and/or changes in the mechanical properties of the parenchyma [53]. In our study, the acute nature of the insults is suggestive of the former. This presents a potential physical mechanism for viral induced exacerbation of asthma symptoms and suggests that future research in this area, in particular those involving animal models, should consider more than just respiratory system resistance.

Despite infecting mice with a relatively high dose of purified HRV-1B ($1 \times 10^8$ TCID$_{50}$), we saw very little effect of HRV-1B infection alone. In fact, the only parameter where HRV-1B alone had a significant effect was on BAL cellular inflammation (Figure 2). This was unexpected as experimental rhinovirus inoculation of human patients with asthma (or of healthy controls) has been shown to increase sensitivity to methacholine [54,55]. The lack of a significant effect of HRV-1B infection on responsiveness or sensitivity to methacholine in our study limits the conclusions that can be inferred from our chosen model of HRV-1B infection. Bartlett et al (2008) showed that infecting adult BALB/c mice with a much lower dose of HRV-1B ($5 \times 10^6$ TCID$_{50}$) resulted in significant changes in a range of lung inflammation and functional parameters [15]. However, the effects seen by Bartlett et al (2008) were often transient, usually peaking 24 hours after infection and resolving within 48–72 hours. We performed our measurements 48 hours after infection, based on preliminary kinetics studies (Figure S1) showing that this timepoint coincides with the peak of pulmonary inflammation in BALB/c mice. However, in taking measurements 48 hours after infection, we may have missed the relatively brief window of significant effects. Other researchers have infected adult mice with the same dose of HRV-1B used in the current study [16,17]. Nagarkar et al (2009) showed that infected mice had significantly higher BAL neutrophils and were significantly more responsive ($R_{aw}$) to inhaled methacholine up to 96 hours post infection [17] when this higher dose was used. This was not seen in a follow-up study, whereby HRV-1B induced neutrophilia had resolved.
48 hours post infection [16]. As with our work, each of these previous studies used purified HRV-1B. The reasons for the relatively small and transient effects of HRV-1B infection in mice despite the high doses used are unknown. There appear to be unknown factors which limit viral replication in mice and result in a steady reduction in titre after infection [49]. This is despite the increase in vRNA 24 hours after infection, indicating positive viral replication. These findings, in conjunction with a lack of an increase in sensitivity to methacholine, strongly supports the notion that timing is critical in experiments involving HRV infection in mice.

Compared with mice infected with HRV-1B alone, much greater effects were seen in mice exposed to HDM alone, with HDM-treated mice exhibiting a range of physiological and immunological characteristics associated with allergen sensitisation. These included significantly increased BAL macrophages, neutrophils and MIP-2 in addition to increased serum total IgE and HDM-specific IgG1 (Figures 2, 3 and 4). Importantly, HDM exposure resulted in impaired baseline lung function and increased responsiveness/sensitivity to methacholine (Figures 5 and 6) 24 hours after the final exposure to HDM. The increased responsiveness to MCh was identified in Rrs, G and H and hence was not restricted to the main conducting airways. In fact, HDM-exposure impaired tissue damping and tissue elastance more severely than it did airway parameters (Figure 5). This suggests that intranasal inoculation of mice with whole-crushed HDM in saline may not elicit a truly allergic response [56], but rather the pathology seen may be a consequence of repeated insult with a mixture of cysteine proteases capable of damaging the lung parenchyma [57]. Again, this implies that researchers should be careful to optimise their HDM model in relation to their specific outcomes of interest.

HDM exposure resulted in significant decreases in IL-13 (a mediator of allergic inflammation) and IFN-α (released by leukocytes for antiviral immunity). Previous studies have demonstrated that asthmatic patients infected with HRV-16 (a major group serotype) had reduced type 1 interferons and IL-13 levels [12,58]. This alteration in innate immunity could partially explain the increased frequency, severity and duration of lower respiratory tract symptoms in asthmatics when compared with healthy patients [59]. As previously mentioned, we did not observe the classical T-helper 2 type pathology induced by HDM exposure identified in previous studies [27,60,61]. For example, we did not detect any BAL IL-5 (a cytokine involved in the production, activation and survival of eosinophils) in HDM-exposed mice, and subsequently nor were any eosinophils identified in BAL. This result was unexpected as we replicated a model which has previously been shown to elicit a TH2 type pathology [60]. The HDM we used was 17.35% w/w HDM protein and contained 23.44 μg DerP/mg protein and 12.47 EU/mg of endotoxin. This is very similar to that employed by Gregory et al (2009) which contained 21.26 μg DerP/mg protein and 13.55 EU/mg of endotoxin. In the Gregory et al (2009) study, adult female BALB/c mice intranasally exposed to 25 μg of HDM protein in saline 5 days per week for 2 weeks had significantly increased airway resistance, lung and BAL eosinophilia and neutrophilia, IL-4, IL-5 and IL-13 compared to controls 24 hours after the final exposure [60]. The HDM composition, dose, timing and method of exposure employed by Gregory et al (2009) are all very similar to those used in the present study, such that discrepancies in results are difficult to interpret. Other studies have shown that HDM extracts with low serine and cysteine protease activity induce greater allergen sensitisation and asthma symptoms (including inflammation and increased TH2 cytokine levels in vivo) compared with extracts higher in proteases [62]. These data show that proteases in HDM extracts are not required in vivo for allergic sensitisation and eosinophilic inflammation and that the induction of allergic airways disease in mice is also independent of LPS levels. This is contrary to certain human data which show that the severity of asthma symptoms (including changes in FEV₁ and the need for daily corticosteroid use) are directly correlated with the concentration of endotoxin in HDM. HDM extracts are complex mixtures, which induce both innate and adaptive immune responses and the properties of the particular HDM preparation used dictates the immune response and ensuing physiological responses [57]. The lack of eosinophilia and associated mediators may not be of critical importance in our model as the dissociation between pulmonary eosinophilia and AHR in allergic airways disease is well known, albeit controversial. Airways hyper-responsiveness has been shown to develop in BALB/c mice in the absence of airway eosinophilia [42,43], and that high BAL eosinophilia does not necessarily correlate with increased AHR [44]. More recently it has been shown that eosinophils play a negligible role in the generation of HDM-induced allergic immunity and airway remodelling in mice [63].

In summary, the present study investigated the effects of HRV-1B infection on HDM-induced asthma in adult female BALB/c mice. As seen in previous studies employing mouse models of HRV infection, the effects of HRV-1B infection alone were transient and considerably milder than the pathology induced by HDM alone. The mild pathology induced suggests that the mouse model of HRV-1B infection requires further optimisation, or that efforts should be focussed on developing a mouse model of HRV infection with a member of the HRV-C group. Further, while HDM exposure did not result in a classical TH2-driven response (such as BAL eosinophilia), there were significant effects of HDM exposure on most parameters measured, including increased cellular inflammation (primarily macrophages and neutrophils), AHR, increased lung tissue responsiveness, and increased total IgE and HDM-specific IgG1. This suggests that certain HDM-based models of allergic airway disease may be appropriate for recapitulation of the human non-eosinophilic asthma phenotype. This is supported by our finding that the greatest additive effects of HDM and HRV-1B were with respect to increased neutrophilia. We also identified additive effects on lung parenchymal responsiveness and noted differences in airway epithelial structure between infected and uninfected mice. This supports the notion of HRV-induced damage to the airway epithelium may facilitate allergen sensitization and/or exacerbation of an asthmatic phenotype. In conclusion, acute rhinovirus infection was found to exacerbate house-dust-mite induced lung disease in adult BALB/c mice.

Supporting Information

Figure S1 HRV-1B infection induces a peak inflammatory response 48 hours after infection in mice. Adult female BALB/c mice were infected with 5 x 10⁶ TCID₅₀ HRV-1B in 50 μL DMEM, or UV-inactivated HRV-1B. Bronchoalveolar lavage fluid was obtained from separate groups of 8–10 mice on days 1–9, 14 and 21 after infection. Numbers of macrophages (A) and neutrophils (B) were determined by light microscopy as described above. * indicates a significantly greater number of cells compared to control. Data are mean ± standard deviation (TIF).
Acknowledgments

The authors thank Rachel Foong, Kara Perks, Kak-Ming Ling and Thomas Ioossifis for assistance with various technical aspects of this work.

Author Contributions

Conceived and designed the experiments: JAP ANL. Performed the experiments: JAP LJB ANL. Analyzed the data: JAP AK LBF GRZ PDS ANL. Contributed reagents/materials/analysis tools: JAP AK LBF LBF GRZ PDS ANL. Wrote the paper: JAP ANL.

References

1. Eadie MB, Stott E, Grist N (1966) Virological studies in chronic bronchitis. British medical journal 2: 671.
2. Sternhause A (1987) Rhinovirus infection in acute exacerbations of chronic bronchitis: a controlled prospective study. British medical journal 3: 461.
3. Lambert H, Stern H (1972) Infective factors in exacerbations of bronchitis and asthma. British medical journal 3: 323.
4. Jackson DJ, Johnston SL (2010) The role of viruses in acute exacerbations of Lower Airways Inflammation during Rhinovirus Colds in Normal and in Asthmatic Subjects. American Journal of Respiratory and Critical Care Medicine 181: 1007–1014.
5. Nicholson KG, Kent J, Ireland DC (1993) Respiratory viruses and exacerbations of asthma in adults. BMJ 307: 982–986.
6. Busse WW, Gern JE (1997) Viruses in asthma. Journal of Allergy and Clinical Immunology 100: 147–150.
7. Wark PAB, Johnston SL, Bucchieri F, Powell R, Puddicombe S, et al. (2005) Community study of viral infections in exacerbations in 9–11 year-old children. BMJ 310: 1225–1229.
8. Jackson DJ, Gangnon RE, Evans MD, Roberg KA, Anderson EL, et al. (2008) Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med 201: 937–947.
9. Fahrenk GL, Bardin PG, Sanderson G, Lamp F, Johnston SL, et al. (1995) Lower Airway Rhinovirus Burden and the Seasonal Risk of Asthma Exacerbation. American Journal of Respiratory and Critical Care Medicine 151: 879–886.
10. Halperin S, Eggelston V, Peasley P, Suratt P, Headley J, et al. (1985) Exacerbations of asthma: Lauder and a preliminary report of an experimental rhinovirus infection. The American review of respiratory disease 132: 976.
11. Bartlett NW, Walton RP, Edwards MR, Aniscenko J, Caramori G, et al. (2008) Viral Burden and the Seasonal Risk of Asthma Exacerbation. Journal of the American Medical Association 300: 494–502.
12. Wark PAB, Johnston SL, Bucchieri F, Powell R, Puddicombe S, et al. (2005) Effect of Human Rhinovirus 16 Colds on Airway Hyperresponsiveness and Lung Function in Asthma. Journal of Allergy and Clinical Immunology 116: 769–774.
13. Ordon˜ez CL, Shaughnessy TE, Matthay MA, Fahy JV (1999) Dissociation of airway hyperresponsiveness from immunoglobulin E and airway eosinophilia in a murine model of asthma in mice. J Exp Med 201: 937–947.
14. Lee W-M, Monroe S, Rhee Y-R, Huang J, Han J, et al. (2009) Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation. Nat Med 15: 199–204.
15. Davis DR, Young MJ, Yoon K, Lee W-M, Hsu S, et al. (2009) Rhinovirus infection of allergen-sensitized and-challenged mice induces eotaxin in a murine model of allergic asthma. American Journal of Respiratory Cell & Molecular Biology 40: 55–59.
16. Larcombe AN, Foong RE, Bozanich EM, Berry LJ, Garratt LW, et al. (2011) Analysis of airway hyperresponsiveness in a murine model of asthma in mice. Current allergy and asthma research 7: 2226–2231.
17. Vlahos R, Koulouris G, Papadopoulos K, Tsangaris T, Karatzia M, et al. (2001) Respiratory syncytial virus infection in asthmatic children: the role of airway hyperresponsiveness. European Respiratory Journal 18: 714–723.
18. Kimb KW, Liub J, Steinhoff MJ, Chauhan A, Fuhlbrigge A, et al. (2008) Impaired airway hyperresponsiveness in asthmatic children with a history of Rhinovirus infection. J Pediatr 153: 963–968.
19. Kuypers J (2010) Molecular detection of rhinoviruses. Expert Review of Molecular Medicine 12: 1–24.
20. Norzila M, Fakes K, Henry RL, Lamp F, Johnston SL, et al. (2011) Association between human rhinovirus C and severity of acute asthma in children. Eur Respir J 37: 1037–1042.
21. Johnston SL, Patterson MK, Sanderson G, Smith S, Lamp F, et al. (1995) Community study of viral infections in exacerbations in 9–11 year-old children. BMJ 310: 1225–1229.
22. Jackson DJ, Gangnon RE, Evans MD, Roberg KA, Anderson EL, et al. (2008) Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med 201: 937–947.
23. Ordon˜ez CL, Shaughnessy TE, Matthay MA, Fahy JV (2000) Increased airway hyperresponsiveness in asthma via a GM-CSF-mediated mechanism. Journal of Immunology 164: 6304–6309.
24. Langford IC, Sorkness RL, Lee WM, Evans MD, Wolff MJ, et al. (2011) Lower Airway Rhinovirus Burden and the Seasonal Risk of Asthma Exacerbation. American Journal of Respiratory and Critical Care Medicine 183: 1007–1014.
25. Kirkland MJ, Caskey CL, Caskey TK, Caskey BP, Caskey RT, et al. (1992) A Panel of Rhinovirus Infection Mouse Models. The Journal of Immunology 148: 55–59.
26. Gru¨nberg K, Timmers M, Smits H, Klerk E, Dick E, et al. (1997) Effect of Human Rhinovirus 16 Colds on Airway Hyperresponsiveness and Lung Function in Asthma. Journal of Allergy and Clinical Immunology 100: 147–150.
27. Lee W-M, Monroe S, Rhee Y-R, Huang J, Han J, et al. (2009) Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation. Nat Med 15: 199–204.
28. Davis DR, Young MJ, Yoon K, Lee W-M, Hsu S, et al. (2009) Rhinovirus infection of allergen-sensitized and-challenged mice induces eotaxin in a murine model of allergic asthma. American Journal of Respiratory Cell & Molecular Biology 40: 55–59.
29. Larcombe AN, Foong RE, Bozanich EM, Berry LJ, Garratt LW, et al. (2011) Analysis of airway hyperresponsiveness in a murine model of asthma in mice. Current allergy and asthma research 7: 2226–2231.
30. Vlahos R, Koulouris G, Papadopoulos K, Tsangaris T, Karatzia M, et al. (2001) Respiratory syncytial virus infection in asthmatic children: the role of airway hyperresponsiveness. European Respiratory Journal 18: 714–723.
31. Hantos Z, Daroczy B, Suki B, Nagy S, Fredberg JJ (1992) Input impedance and peripheral inhomogeneity of dog lungs. Journal of Applied Physiology 72: 168–176.
32. Hofer F, Gruenberger B, Kooslad H, Machat H, Hueteringer M, et al. (1994) Members of the low density lipoprotein receptor family mediate cell entry of a minor-group common cold virus. Proceedings of the National Academy of Sciences 91: 1839–1842.
33. Tuthill TJ, Papadopoulos NG, Jourdain P, Challinor LJ, Sharp NA, et al. (2003) Mouse respiratory epithelial cells support efficient replication of human rhinovirus. J Gen Virol 84: 2829–2836.
34. Lee W-M, Monroe S, Rhee Y-R, Huang J, Han J, et al. (2009) Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation. Nat Med 15: 199–204.
35. Davis DR, Young MJ, Yoon K, Lee W-M, Hsu S, et al. (2009) Rhinovirus infection of allergen-sensitized and-challenged mice induces eotaxin release from functionally polarized macrophages. The Journal of Immunology 185: 2226–2231.
36. tidal volume (Vt) and the slope of the positive pressure (Plateau) vs. the initial airway pressure (Paw) relationship. The Journal of Applied Physiology 72: 168–176.
and interleukin-8 in nasal lavage in asthmatic subjects in vivo. Clinical & Experimental Allergy 27: 36–45.
49. Hershenson MB (2013) Rhinovirus-Induced Exacerbations of Asthma and COPD. Scientifica 2013: 12.
50. Lundblad L, Irvin C, Hantos Z, Sly P, Mitzner W, et al. (2007) Penh is not a measure of airway resistance! European Respiratory Journal 30: 805–805.
51. Irvin CG, Bates JHT (2003) Measuring the lung function in the mouse: the challenge of size. Respiratory Research 4: 4.
52. Bates JH, Irvin CG (2002) Time dependence of recruitment and derecruitment in the lung: a theoretical model. Journal of Applied Physiology 93: 705–713.
53. Bates JH, Irvin CG (2003) Measuring lung function in mice: the phenotyping uncertainty principle. Journal of Applied Physiology 93: 1297–1306.
54. Cheung D, Dick EC, Timmers MC, & Kleer EP, Spaan WJ, et al. (1995) Rhinovirus infection causes long-lasting excessive airway narrowing in response to methacholine in asthmatic subjects in vivo. American Journal of Respiratory and Critical Care Medicine 152: 1490–1496.
55. Lemanske R Jr, Dick E, Swenson C, Veis R, Buze W (1989) Rhinovirus upper respiratory infection increases airway hyperreactivity and late asthmatic reactions. J Clin Invest 83: 1–10.
56. Birrell M, Van Oosterhout A, Belvisi M (2010) Do the current house dust mite-driven models really mimic allergic asthma? European Respiratory Journal 36: 1220–1221.
57. Gregory LG, Lloyd CM (2011) Orchestrating house dust mite-associated allergy in the lung. Trends in Immunology 32: 492–411.
58. Papadopoulos NG, Stanciu LA, Papi A, Holgate ST, Johnston SL (2002) A defective type 1 response to rhinovirus in atopic asthma. Thorax 57: 320–332.
59. Corne JM, Marshall G, Smith S, Schechter J, Sanderson G, et al. (2002) Frequency, severity, and duration of rhinovirus infections in asthmatic and non-asthmatic individuals: a longitudinal cohort study. Lancet 359: 831–834.
60. Gregory L, Causton B, Murdoch J, Mathie S, O'Donnell V, et al. (2009) Inhaled house dust mite induces pulmonary T helper 2 cytokine production. Clinical & Experimental Allergy 39: 1297–1310.
61. Phipps S, Lam CE, Kako GE, Foo SY, Collison A, et al. (2009) Toll/IL-1 Signaling Is Critical for House Dust Mite–specific Th1 and Th2 Responses. American Journal of Respiratory and Critical Care Medicine 179: 883–893.
62. Post S, Nosjin M, Hackett T, Baranowska M, Greer R, et al. (2012) The composition of house dust mite is critical for mucosal barrier dysfunction and allergic sensitisation. Thorax 67: 490–495.
63. Fattouh R, Al-Garawi A, Fattouh M, Arias K, Walker TD, et al. (2011) Eosinophils Are Dispensable for Allergic Remodeling and Immunity in a Model of House Dust Mite–induced Airway Disease. American Journal of Respiratory and Critical Care Medicine 183: 179–188.